Keros Therapeutics (KROS) Enterprise Value (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Enterprise Value came in at -$287.4 million in Q4 2025, up 48.67% YoY from -$193.3 million in Q4 2024, and up 58.56% on a QoQ basis from -$693.5 million in Q3 2025.
Keros Therapeutics (KROS) Enterprise Value (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Enterprise Value data on file, last reported at -$287.4 million in Q4 2025.
- Quarterly Enterprise Value rose 48.67% year-over-year to -$287.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$287.4 million (up 48.67% YoY) and the FY2025 annual result came in at -$287.4 million, up 48.67% from the prior year.
- Enterprise Value rose to -$287.4 million in Q4 2025, from -$693.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$215.6 million in Q2 2022 to a low of -$720.5 million in Q1 2025.
- A 5-year average of -$376.5 million and a median of -$305.0 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value plunged 368.11% — and 2025, when it soared 48.67%.
- Tracing KROS's Enterprise Value over 5 years: stood at -$230.0 million in 2021, then declined by 21.3% to -$279.0 million in 2022, then retreated by 18.67% to -$331.1 million in 2023, then sank by 69.09% to -$559.9 million in 2024, then soared by 48.67% to -$287.4 million in 2025.
- The last three Enterprise Value figures came in at -$287.4 million (Q4 2025), -$693.5 million (Q3 2025), and -$690.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | -257.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -257.61 Mn |
| Dec 31, 2025 | -287.40 Mn |
| Sep 30, 2025 | -693.47 Mn |
| Jun 30, 2025 | -690.22 Mn |
| Mar 31, 2025 | -720.54 Mn |
| Dec 31, 2024 | -559.93 Mn |
| Sep 30, 2024 | -530.68 Mn |
| Jun 30, 2024 | -405.86 Mn |
| Mar 31, 2024 | -442.44 Mn |
| Dec 31, 2023 | -331.15 Mn |
| Sep 30, 2023 | -287.89 Mn |
| Jun 30, 2023 | -322.03 Mn |
| Mar 31, 2023 | -351.43 Mn |
| Dec 31, 2022 | -279.05 Mn |
| Sep 30, 2022 | -239.43 Mn |
| Jun 30, 2022 | -215.62 Mn |
| Mar 31, 2022 | -228.59 Mn |
| Dec 31, 2021 | -230.04 Mn |
| Sep 30, 2021 | -221.35 Mn |
| Jun 30, 2021 | -237.11 Mn |